Evidence map›Paper›PMID 42375372›Full record

ArticleFrontiers in immunology2026

Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor.

Isabelle Panne, Matthias Matter, Jürg Vosbeck, Matthias von Rotz, Alexandra Steinemann, Marten Trendelenburg, Markus H Heim, Peter Schirmacher, Andrea De Gottardi, Ansgar W Lohse and 2 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Isabelle PanneUniversity Centre for Gastrointestinal and Liver Diseases, University Hospital, Basel, Switzerland.
Matthias MatterDepartment of Pathology, University Hospital, Basel, Switzerland.
Jürg VosbeckDepartment of Pathology, University Hospital, Basel, Switzerland.
Matthias von RotzDepartment of Infectious Diseases, University Hospital, Basel, Switzerland.
Alexandra SteinemannDepartment of Ophthalmology, University Hospital, Basel, Switzerland.
Marten TrendelenburgUniversity Hospital Basel and Clinical Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Markus H HeimUniversity Centre for Gastrointestinal and Liver Diseases, University Hospital, Basel, Switzerland.
Peter SchirmacherDepartment of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Andrea De GottardiGastroenterology and Hepatology, Luzerner Kantonsspital, Luzern, Switzerland.
Ansgar W LohseDepartment of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Luigi M TerraccianoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Christine BernsmeierUniversity Centre for Gastrointestinal and Liver Diseases, University Hospital, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyoderma gangrenosum is a rare autoimmune condition that is difficult to diagnose and primarily affects the skin. Extracutaneous manifestations, including hepatic involvement, occur only rarely. Here, we report a case of extracutaneous manifestation of pyoderma gangrenosum without adjunct skin lesions, emphasizing the diagnostic challenges, immunological considerations, and therapeutic implications. This case describes a 73-year-old man presenting with isolated hepatic and ocular involvement of pyoderma gangrenosum, without skin lesions and without an underlying chronic inflammatory disease. This case aims to expand the clinical understanding of the spectrum of pyoderma gangrenosum, reinforce its systemic nature, and contribute to improved recognition of extracutaneous disease involvement even without primary skin manifestation. The patient exhibited fever, weight loss of 3 kg within 3 weeks, elevated hepatocellular and cholestatic liver parameters (AST: 128 U/L, upper limit norm [ULN]: 34 U/L; ALT: 116 U/L, ULN: 59 U/L), and elevated CRP (147.5 mg/L, ULN: 10 mg/L). Imaging revealed disseminated nodular liver lesions. Histology demonstrated sterile abscesses and granulomatous inflammation. Ophthalmologic examination revealed conjunctival injections and granulomatous uveitis. No other organs were involved. Extensive testing excluded infectious or other immunological causes. After comprehensive screening for infectious, rheumatological, malignant, or hematological diseases, systemic inflammatory syndromes, and drug-induced liver injury, none of the suspected common diagnoses could be confirmed. In relation to the distinctive histological pattern resembling a few published case reports, we assumed pyoderma gangrenosum with hepatic and ocular involvement without skin lesions. We initiated immunosuppressive treatment with prednisone, followed by infliximab. This strategy successfully led to symptom resolution and complete clinical and biochemical remission. This case highlights the diagnostic challenges of granulomatous liver injury and pyoderma gangrenosum at unusual sites. Pyoderma gangrenosum is a rare condition, particularly when presenting with isolated hepatic and ocular involvement, and may be considered a differential diagnosis underlying granulomatous hepatic injury. Using a TNF-alpha inhibitor, we successfully achieved a complete remission.

Indexed as

GranulomaLiver DiseasesPyoderma GangrenosumTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAgedHumansMaleTreatment OutcomeTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitorsextracutaneous manifestationgranulomatous liver diseasepyoderma gangrenosumTNF – alpha inhibitortreatment

Identifiers

PMID42375372
PMCPMC13311106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.